Lighthouse Investment Partners LLC Acquires Shares of 9,400 Cencora, Inc. (NYSE:COR)

Lighthouse Investment Partners LLC bought a new position in Cencora, Inc. (NYSE:COR - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 9,400 shares of the company's stock, valued at approximately $2,112,000.

Several other large investors also recently added to or reduced their stakes in the stock. JFS Wealth Advisors LLC lifted its holdings in Cencora by 63.0% during the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after buying an additional 46 shares during the period. Banque Transatlantique SA acquired a new stake in Cencora in the 4th quarter valued at about $29,000. SBI Securities Co. Ltd. acquired a new stake in shares of Cencora during the 4th quarter worth approximately $30,000. Kentucky Trust Co purchased a new position in Cencora in the fourth quarter valued at $33,000. Finally, Householder Group Estate & Retirement Specialist LLC boosted its holdings in Cencora by 85.2% in the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock valued at $33,000 after purchasing an additional 69 shares during the period. 97.52% of the stock is owned by institutional investors.

Insider Activity

In other news, EVP Silvana Battaglia sold 5,000 shares of the company's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the sale, the executive vice president now owns 15,374 shares in the company, valued at approximately $3,724,197.76. This represents a 24.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Chairman Steven H. Collis sold 14,578 shares of the company's stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the completion of the transaction, the chairman now owns 317,913 shares of the company's stock, valued at approximately $85,680,732.63. This trade represents a 4.38% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 50,223 shares of company stock valued at $13,580,967. Company insiders own 10.80% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on COR. UBS Group boosted their price target on Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a research report on Tuesday, April 29th. Morgan Stanley set a $288.00 target price on Cencora in a research report on Tuesday, April 15th. Evercore ISI lifted their target price on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research note on Thursday, February 6th. StockNews.com raised Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Finally, Wells Fargo & Company increased their price target on Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research report on Friday, March 14th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $301.18.

Cencora Price Performance

Shares of Cencora stock traded up $4.27 during trading hours on Friday, reaching $290.24. The company's stock had a trading volume of 1,355,556 shares, compared to its average volume of 1,542,582. The stock has a market cap of $56.28 billion, a P/E ratio of 41.29, a P/E/G ratio of 1.31 and a beta of 0.60. Cencora, Inc. has a one year low of $214.77 and a one year high of $309.35. The firm has a 50 day moving average price of $279.10 and a 200-day moving average price of $254.99. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54.

Cencora (NYSE:COR - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, beating analysts' consensus estimates of $4.07 by $0.35. The company had revenue of $75.50 billion during the quarter, compared to analysts' expectations of $75.41 billion. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Cencora's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.80 earnings per share. On average, analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, June 2nd. Stockholders of record on Friday, May 16th will be paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.76%. The ex-dividend date of this dividend is Friday, May 16th. Cencora's dividend payout ratio (DPR) is 25.52%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.